---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001422"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:04:44.202663+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q4 revenue $24.6M, FY 2024 net loss widens to $12.4M

## Summary
- Q4 2024 revenue $24.6M, down 12.8% from $28.2M in Q4 2023.
- Full-year 2024 revenue $94.1M vs $112.3M; net loss $(12.4)M vs $(3.4)M.
- Adjusted EBITDA fell to $7.2M from $14.6M; operating cash flow dropped to $1.4M from $14.0M.
- CEO cites challenging market; highlights SoHo telemetry and MeshMEA organoid systems as growth drivers.
- Q4 net income was $18K vs loss of $(1.8)M in Q4 2023 (slight improvement in quarter).

## SEC filing metadata
- accession: 0001171843-25-001422
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325001422/0001171843-25-001422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325001422/f8k_031225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001422
- JSON: https://secwatch.observer/filing/0001171843-25-001422.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.